Autoimmune Diseases  >>  losmapimod (FTX-1821)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
losmapimod (FTX-1821) / Fulcrum Therap
NCT00256919 / 2005-002969-37: Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)

Completed
2
51
Europe, RoW
GW856553
GlaxoSmithKline
Arthritis, Rheumatoid
11/06
11/06
NCT00393146 / 2006-001234-40: A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis

Completed
2
57
Europe, RoW
GW856553
GlaxoSmithKline
Arthritis, Rheumatoid
01/08
01/08

Download Options